Revivent System Used Via LIVE Procedure In Italy
BioVentrix has reported the successful clinical use of its Revivent myocardial anchoring system, via Less Invasive Ventricular Enhancement or the LIVE procedure in three clinical procedures all conducted by Professor Claudio Muneretto, Director of the department of cardiac surgery, the Ospedale Civile, in Brescia, Italy. The successful procedures, used to reshape the left ventricle (LV), were performed on three patients, all men ages 68 to 77 years, suffering from advanced HF.
Professor Muneretto, stated that these patients were all experiencing a very poor quality of life before the LIVE procedure. Immediately after the procedure, the volume of the LV of each patient was reduced by 25-35%, and importantly, the procedures were performed without complications. The LIVE procedure and Revivent system provide a much-needed option for patients suffering from heart failure, particularly when medical therapy is no longer effective. The LIVE procedure using the Revivent system is performed without the need of cardiopulmonary bypass or making incisions into the heart.
The Revivent system received CE mark in December 2012 and clinical use has expanded from Eastern European clinical sites to major Western European markets including Germany, France, Portugal, Italy, and the UK. David Schickling, Vice President of sales and marketing at BioVentrix, stated that while clinical adoption of the Revivent system continues to grow, the company's forthcoming Revivent-TC product, a hybrid transcatheter approach, will enable even more patients to benefit from this technology.
The Revivent-TC and Revivent myocardial anchoring systems address the safety concerns of physicians about subjecting patients to invasive surgical interventions on the LV of the heart. The system, comprised of a series of titanium anchor pairs placed using transmural catheters, pulls the lateral LV wall toward the septum to create a fold of tissue that effectively excludes the non-functioning scar created by a previous myocardial infarction. This restores the LV to a more optimal, conical shape, which enhances the pumping efficiency of the remaining myocardium. The Revivent-TC system is designed for use in the interventional laboratory whereas the Revivent system is for use in the operating room when the patientâs chest has been opened for a concurrent cardiac procedure.
The LIVE procedure is based upon a law of physics called the law of Laplace, which describes the relationship between the radius and pressure of the LV, and its resulting wall tension. Increased wall tension is the underlying cause of LV enlargement, worsening heart failure symptoms and ultimately patient death. Reducing wall tension is key to preventing further LV enlargement and treats the progression of the disease. The Revivent system, placed via the LIVE procedure, is designed to directly reduce the LV radius, which in turn decreases wall tension and interrupts the ongoing, destructive process of heart failure.